<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report: April 4, 1997
DEPUY, INC.
(Exact name of registrant as specified in its charter)
<TABLE>
<CAPTION>
<S> <C> <C>
Delaware 001-12229 35-1989795
(State of (Commission (IRS Employer
Incorporation) File Number) Identification No.)
</TABLE>
700 Orthopaedic Drive
Warsaw, Indiana 46581-0988
(Address of principal executive offices) (Zip Code)
(219) 267-8143
(Registrant's telephone number, including area code)
Page 1 of 5
<PAGE>
Item 5. Other Events
The Registrant's news release dated April 2, 1997, a copy of which is
attached as Exhibit 1 hereto, is incorporated herein by reference and made a
part hereof.
Page 2 of 5
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
DEPUY, INC.
Date: April 4, 1997
By: /s/ Steven L. Artusi
-----------------------
Name: Steven L. Artusi
Title: Senior Vice President,
General Counsel and
Secretary
Page 3 of 5
<PAGE>
EXHIBIT INDEX
Exhibit No. Description Page No.
- ----------- ----------- --------
1. News Release dated April 2, 1997 5
Page 4 of 5
<PAGE>
[DePuy LOGO]
CONTACT: JIM GOFF
DIRECTOR, INVESTOR RELATIONS
(219) 372-7305
Acquisition of Landanger-Camus by DePuy, Inc.
WARSAW, Ind. and PARIS, April 2 /PRNewswire/ -- In accordance with the
agreement signed on February 28, 1997, DePuy Orthopedie S.A., a subsidiary of
DePuy, Inc., has directly and indirectly acquired effective April 1, a total
1,939,453 shares (i.e. 89.6% of the capital) of Landanger-Camus at a price per
share of 359.11 francs, or US$63.85 at the exchange rate as of April 1, 1997.
This price may be increased or decreased in the coming weeks, notably depending
on the results of an audit of the Landanger-Camus group.
Trading of the Landanger-Camus shares will be suspended pending the
launching of a simplified tender offer for the remaining shares to be carried
out by a price guarantee procedure which, depending on the results, will be
followed by a mandatory buy-out procedure.
DePuy is the world's oldest orthopaedic company and is one of the leading
designers, manufacturers and distributors of orthopaedic devices and supplies.
Its products are used primarily by orthopaedic medical specialists and, in the
case of the Company's spinal implants, spinal and neurosurgeons. The products
are used in both surgical and non-surgical therapies to treat patients with
musculoskeletal conditions resulting from degenerative diseases, deformities,
trauma and sports-related injuries.
SOURCE DePuy, Inc.
-0- 04/02/97
/CONTACT: Jim Goff, Director of Investor Relations, DePuy, Inc.,
219-372-7305/
Page 5 of 5
